Ramelteon; Placebo
Проводит Takeda
Страница компанииA Randomised, Double-blind, Placebo-controlled Study to Determine the Long-term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia.
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00247390/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 451 чел. во всех странах исследования.
- Плановая дата окончания (12.2006) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- Индекс массы тела18–34 кг/м²
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 43
Критерии включения
- Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.
- Body mass index between 18 and 34, inclusive.
- Based on sleep history, has had chronic insomnia for at least 3 months.
- Based on sleep history, reports a subjective sleep latency greater than or equal to 45 min and a subjective total sleep time less than or equal to 6.5 hours.
- Based on sleep history, habitual bedtime is between 10:00 PM and 1:00 AM.
- Mean latency to persistent sleep of greater than 20 minutes on two consecutive screening nights with neither night less than 15 minutes. Also, a mean of 60 minutes of wake time during the 480 minutes in bed across two nights with no night less than 45 minutes.
- Based on sleep history, normally uses pharmacological assistance to sleep 0 to 4 times per week in the last 3 months.
Критерии невключения
- Known hypersensitivity to ramelteon or related compounds, including melatonin, and melatonin related compounds.
- Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer.
- Sleep schedule changes required by employment (eg, shift worker) within three months prior to the administration of single-blind study medication.
- Flown across greater than three time zones within 7 days prior to or during screening.
- Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of single-blind study medication.
- Has ever had a history of seizures, sleep apnea, restless leg syndrome, periodic leg movement syndrome, chronic obstructive pulmonary disease or fibromyalgia.
- History of psychiatric disorder within the past 6 months.
- History of alcohol abuse within the past 12 months, as defined in Diagnostic \& Statistical Manual of Mental Disorders, 4th Edition Revised, or regularly consumes more than 14 alcoholic drinks per week, or consumed any alcoholic drinks within 24 hours of any polysomnogram visits.
- History of drug abuse within the past 12 months, as defined in Diagnostic \& Statistical Manual of Mental Disorders, 4th Edition Revised.
- Current significant hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, neurological, or metabolic disease, unless currently controlled and stable with protocol-allowed medication, within 30 days prior to the first night of single-blind study medication.
- Apnea hypopnea index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night.
- Periodic Leg Movement Syndrome with arousal index (per hour of sleep) greater than 10 as seen on the first polysomnogram screening night.
- Positive urine drug screen at Screening Visit 1 or any of the polysomnogram assessment visits.
- Positive breathalyzer test on any of the polysomnogram assessment visits.
- Uses tobacco products (including nicotine gum and patch) or any other products that may interfere with the sleep wake cycle during nightly awakenings.
- Used any central nervous system medication or other drugs or supplements known to affect sleep/wake function within 1 week (or 5 half lives of the drug, whichever is longer) prior to the administration of single-blind study medication. These medications must not have been used to treat psychiatric disorders.
- Intends to continue taking any disallowed medication or any prescription medication or over the counter medication that is known to affect the sleep/wake function or otherwise interfere with evaluation of the study medication. The subject must report all prescription and over the counter medications taken in the three weeks prior to screening.
- Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
- Anxiolytics
- Sedatives
- Hypnotics
- CNS active drugs (including herbal)
- Antidepressants
- Narcotic analgesics
- Anticonvulsants
- Beta blockers
- Sedating H1 antihistamines
- St. John's Wort
- Systemic steroids
- Kava-kava
- Respiratory stimulants
- Ginkgo-biloba
- Decongestants
- Over-the-counter and prescription stimulants
- Antipsychotics
- Over-the-counter and prescription diet aids
- Muscle Relaxants
- Melatonin and all other drugs or supplements known to affect sleep/wake function
- Any additional condition(s) that in the Investigator's opinion would
- affect sleep/wake function
- prohibit the subject from completing the study
- indicate that continuation in the study would not be in the best interests of the subject.
- History of hepatitis B or hepatitis C.
Источник: ClinicalTrials.gov, NCT00247390 · запись обновлена в реестре 3 июня 2010.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 11
- Mean change in Latency to Persistent Sleep of 2-night polysomnogram. — Months 3 and 6 or Final Visit
Цель исследования
The purpose of this study to determine the long-term efficacy and safety of ramelteon, once daily (QD).
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00247390 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.